Clinical Biomarker Discovery Initiative would speed progress in early detection and measurement of response to therapy, Leland Hartwell tells NCI.
Also in this 8-page issue: Dept. of Justice, Congress to investigate Merck and FDA actions on Vioxx; FDA asks IOM to study its monitoring system for approved drugs.
NCI appoints Robert Young chairman of the Board of Scientific Advisors, reappoints Ellen Sigal, and names 11 new members to board. Earnest Hawk to direct NCI Office of Centers, Training and Resources.
St. Jude Children’s wins NCI contract for Pediatric Preclinical Testing Program.
Funding opportunities listed.
Trending Stories
- NIH Director Jay Bhattacharya launches a podcast
- As Trump decimates NIH funding, a daring proposal to issue $750 billion in bonds for medical cures garners attention
- Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures
- “Forward funding” NIH budget plan would make competing for grants much harder
- Optimizing dosing of expensive and toxic oncology drugs: Making America healthier
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”